Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The minimal side effects observed were mainly flares of MCAS-driven symptoms in response to initial dosing, which were easily managed with extra doses of H1/H2 receptor blockers
and the potential launch or commercialization of any of Companys product candidates or products and our strategic and product development objectives and goals, and the other factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025 and in our other filings with the SEC
Any pattern of progressively worsening reactions with subsequent injections warrants prompt medical evaluation
(2025) 104(1_suppl):339s44
US$ 28.89
US$ 26.07
US$ 26.34
US$ 21.21
